| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Coeptis Therapeutics Holdings, Inc.$16.4
+0.17 (+1.05%)
D 25Pipeline Score Richly Valued Biotech · Clinical
Market Cap
102.06 M
EPS
-2.80
P/E Ratio
-
Value Trade
1.85 M
SEC Financials
Q1 2026Dilution Risk
Revenue
113.77 K
R&D Expenses
235.53 K
Operating CF
-1.76 M
Total Assets
19.79 M
Total Liabilities
2.21 M
Equity
17.18 M
D/E Ratio
12,345
17.23 %
Week
57.69 %
1 Month
15.74 %
3 Month
2.31 %
6 Month
-91.72 %
5 Year
-91.72 %
All Time
Cash Data
Cash Position
5.21 M
Monthly Burn
586.00 K
Runway
7.2 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
111.93 K
52 Week Range
6.80 - 21.41
% held by Insiders
18.15 %
% held by Institutions
7.47 %
Enterprise Value
96.48 M
Total Shares
5.34 M
Short %
9.41 %
Float Shares
4.57 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D25
Pipeline Score $3M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 24%
Micro Cap (rank 694 of 912)
Percentile RankCoeptis Therapeutics Holdings, Inc. faces pipeline headwinds (25/100), with $391M risk-adjusted pipeline value, led by DVX201 in COVID-19 Pneumonia (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DVX201 Monoclonal antibody | COVID-19 Pneumonia | Phase 1 | NCT04900454 | 22% | $391M | COMPLETED | 12 | - | - | Jun 1, 2022 | - | Apr 7, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in COEP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
COEP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How COEP ranks across every disease it competes inCompetitive Position is a premium feature
See how COEP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial